FridayMar 13, 2026 9:50 am

TinyGemsBreaks – ParaZero Technologies Ltd. (NASDAQ: PRZO) Receives Counter-UAS Order from Israeli Defense Entity

ParaZero Technologies (NASDAQ: PRZO), an aerospace defense company developing autonomous solutions for the global manned and unmanned aerial systems industry, announced it has received a new purchase order from an Israeli defense entity for its DefendAir counter-unmanned aerial systems platform. The order includes delivery of an evaluation kit featuring DefendAir net pods along with live exercises and training intended to support rapid operational deployment and readiness. The DefendAir system uses patented non-explosive net-launcher technology designed to neutralize hostile drones while minimizing collateral impact and addressing evolving aerial threats across urban and battlefield environments. To view the full press release, visit…

Continue Reading

WednesdayMar 11, 2026 9:30 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Launches New Growth Strategy Focused On Neurology And Oncology Pipeline Expansion

CNS Pharmaceuticals (NASDAQ: CNSP) announced a new corporate growth strategy aimed at building a high-value pipeline in neurology and oncology through the acquisition or in-licensing of preclinical and clinical-stage therapeutic assets. Following a comprehensive strategic review incorporating clinical probability-of-success modeling, regulatory pathway analysis and market assessments, the company said it will prioritize programs with differentiated mechanisms, clear development pathways and strong commercial potential, while preparing legacy assets TPI 287 and berubicin for potential out-licensing to focus resources on advancing a new acquisition-driven pipeline. To view the full press release, visit https://ibn.fm/MutVR About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage…

Continue Reading

TuesdayMar 10, 2026 9:20 am

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents TONMYA Data at International Fibromyalgia Congress

Tonix Pharmaceuticals (NASDAQ: TNXP) announced two oral presentations on TONMYA(TM), investigated as TNX-102 SL (cyclobenzaprine HCl sublingual tablets), at the 8th International Congress on Controversies in Fibromyalgia held March 9-10, 2026, in Krakow, Poland. Post hoc analyses from the Phase 3 RESILIENT trial and pooled data from the RELIEF and RESILIENT studies highlighted rapid pain relief and a favorable benefit-risk profile for TONMYA in adults with fibromyalgia, including statistically significant reductions in pain and a likelihood of clinical benefit nearly four times greater than discontinuation due to adverse events. TONMYA, the first medication approved for fibromyalgia in more than 15…

Continue Reading

FridayMar 06, 2026 3:13 pm

TinyGemsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Adds Innovative LiGHT Therapy to Pipeline 

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, which is pioneering proton therapy systems for treating tumors in various types of cancers. “Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship technology, the LiGHT System (Linac for Image Guided Hadron Therapy), which offers many advantages over other technologies that are currently available for treating tumors with proton therapy,” reads an article discussing the move. “The highly adaptable LiGHT System provides a proton beam allowing the delivery of very high dose rates to deep-seated tumors,” said Professor Steve Myers, the former Director of Accelerators and Technology…

Continue Reading

FridayMar 06, 2026 9:12 am

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces Peer-Reviewed Publication Highlighting Pharmacokinetics of TONMYA(TM) Sublingual Tablets 

Tonix Pharmaceuticals (NASDAQ: TNXP), a fully integrated commercial biotechnology company, announced the publication of a peer-reviewed paper detailing results from randomized open-label studies evaluating the pharmacokinetics of TNX-102 SL, the sublingual formulation of cyclobenzaprine HCl marketed as TONMYA(TM). Published in Clinical Pharmacology in Drug Development, the journal of the American College of Clinical Pharmacology, the study highlights how TONMYA’s proprietary basifying agent enables rapid transmucosal absorption that bypasses first-pass hepatic metabolism. The formulation, approved by the U.S. Food and Drug Administration on Aug. 15, 2025, for the treatment of fibromyalgia in adults, is designed to increase parent drug exposure during sleep while reducing exposure to…

Continue Reading

TuesdayMar 03, 2026 10:10 am

TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Approved to Transfer Listing to Nasdaq Global Select Market

Tonix Pharmaceuticals (NASDAQ: TNXP) announced it has received approval from Nasdaq to transfer the listing of its common stock from the Nasdaq Capital Market to the Nasdaq Global Select Market, with trading on the higher tier expected to begin at the open of market on March 3, 2026, under the existing ticker symbol “TNXP.” The move reflects the company’s compliance with the Nasdaq Global Select Market’s more stringent financial and corporate governance requirements and is expected to enhance institutional visibility, liquidity and broader market recognition. Management described the uplisting as an important milestone as the company continues to focus on…

Continue Reading

MondayMar 02, 2026 9:45 am

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Appoints Lynne Kelley as Chief Medical Officer

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing novel treatments for primary and metastatic cancers of the brain and central nervous system, announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer. Dr. Kelley brings more than 20 years of global leadership experience spanning clinical development, translational medicine and regulatory strategy across oncology, rare diseases, CNS and medical devices, having led Phase 1–3 programs and supported regulatory approvals in the United States, Europe, China and Japan. She has previously served as chief medical officer at several biotechnology and medical device companies, including TISSIUM, Servier Pharmaceuticals, X4…

Continue Reading

ThursdayFeb 26, 2026 9:20 am

TinyGemsBreaks – NextPlat Corp (NASDAQ: NXPL) Expands Orbital Satcom Into Five Latin American Markets via Mercado Libre 

NextPlat (NASDAQ: NXPL, NXPLW) announced a major expansion of its Orbital Satcom North American operations into five South American markets through the launch of online storefronts on Mercado Libre, the largest e-commerce platform in Latin America. The new sites will serve customers in Mexico, Brazil, Argentina, Chile and Colombia, offering wireless and satellite-based connectivity products operating on commercial satellite networks including Globalstar, Iridium and Inmarsat. The company said the expansion targets growing regional demand for satellite-enabled voice, data, tracking and safety solutions across South America’s approximately 440 million residents, with additional market launches planned in the second quarter of 2026.…

Continue Reading

WednesdayFeb 25, 2026 9:00 am

TinyGemsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Appoints Jamie MacLaurin SVP of Sports Business, Secures 68% Supermajority of Veloce

SEGG Media (NASDAQ: SEGG, LTRYW) announced that Jamie MacLaurin, co-founder of Veloce Media Group and CEO of Quadrant, was appointed senior vice president of SEGG’s sports business as the company secured supermajority control of approximately 68% of Veloce’s outstanding equity. SEGG indicated it will extend a global offer to acquire the remaining minority interests to streamline governance and align long-term strategy, with Veloce expected to contribute approximately $20 million in annual revenue beginning in Q1 2026. MacLaurin will continue leading Veloce and Quadrant while identifying broader commercial opportunities across SEGG’s sports portfolio, leveraging Quadrant’s creator-led motorsport brand co-founded with 2025…

Continue Reading

TuesdayFeb 24, 2026 10:39 am

TinyGemsBreaks – Rail Vision Ltd. (NASDAQ: RVSN) Featured on Latest TechMediaWire Podcast Episode Released by IBN 

Rail Vision (NASDAQ: RVSN) is featured in the latest episode of The TechMediaWire Podcast released by IBN, which delivers updates and executive interviews across the technology sector. During the episode, CEO David BenDavid discussed the company’s AI-based vision systems designed to provide real-time hazard detection and situational awareness for rail operators, highlighting the value of early threat detection in reducing incidents, damage and downtime. BenDavid also emphasized 2026 priorities centered on commercial scaling, converting pilot programs into repeat orders and expanding strategic partnerships, while noting increasing industry urgency around railway safety and growing receptiveness to advanced detection systems. To view the full press release, visit https://ibn.fm/HQB7E About Rail Vision Ltd. Rail…

Continue Reading

Contact us: (512) 354-7000